BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Wallace, J. L., & Devchand, P. R. (2005). Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. British Journal of Pharmacology, 145(3), 275–282. Added by: Dr. Enrique Feoli (03/04/2022, 17:30) Last edited by: Dr. Enrique Feoli (03/04/2022, 17:31) |
 |
| Resource type: Journal Article DOI: 10.1038/sj.bjp.0706201 ID no. (ISBN etc.): 0007-1188 BibTeX citation key: Wallace2005 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Chronic NSAIDS Creators: Devchand, Wallace Collection: British Journal of Pharmacology |
Views: 4/355
|
| Abstract |
|
The development of selective inhibitors of cyclooxygenase-2 (COX-2) was based on the concept that this enzyme played little, if any, role in modulating the ability of the gastrointestinal (GI) tract to resist and respond to injury. There is now overwhelming evidence that this is far from true. Indeed, COX-2 mediates several of the most important components of ‘mucosal defense', contributes significantly to the resolution of GI inflammation and plays a crucial role in regulating ulcer healing. COX-2 also contributes to long-term changes in GI function after bouts of inflammation.
|